Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance
Labcorp announced its third-quarter 2026 financial results, reporting a 7% year-over-year revenue increase and raising its full-year 2026 guidance.
Stocks · News reference
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp will purchase Myriad Genetics' prenatal testing business for $210 million in cash, projecting $160 million in year-one revenue.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — LABCORP HOLDINGS INC. (LH)
Filed: 2026-10-28 AccNo: 0000920148-26-000213 Size: 736 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Labcorp Partners with Waters Corporation to Expand HPV Testing
Labcorp has entered into a partnership with Waters Corporation to offer the FDA-approved BD Onclarity HPV Assay across its U.S. laboratory network starting in late 2026.
Labcorp, Charles River, and FDA Partner on Drug Abuse Research
Labcorp has entered into a collaborative partnership with Charles River Laboratories and the FDA to conduct research on the potential abuse of medicines.
Myriad Genetics Announces New Data from MONSTAR-SCREEN-3 Study
Myriad Genetics released new data from its MONSTAR-SCREEN-3 study demonstrating the potential of its Precise MRD platform for detecting molecular residual disease in colorectal and pancreatic cancers.
Nasdaq Rises Over 100 Points; 3M Earnings Top Views
U.S. stocks rose Tuesday, led by the Dow, as 3M beat estimates. Braze and Myriad surged, while GM fell; oil and silver gained.